A number of tools are available to assess disease severity and progression in patients with peripheral neuropathies such as CIDP. Gain a better understanding of four of these tools.
The GRIPPER study: Quantifying IVIG Treatment-Related Fluctuations in CIDP Using Daily Grip Strength Measurements
Jeffrey A. Allen, MD
University of Minnesota
12:15 MIN
CIDP
Learn more about grip strength as an outcome measure in CIDP and how it is utilized in the Gripper Study as a daily measure of treatment-related fluctuations in IVIg-treated patients.
Claudia Sommer is a Professor of Neurology at the University of W├╝rzburg, Germany.
Mel Berger, MD, PhD
Medical Research Strategy, CSL Behring
Mel Berger, MD, PhD
Medical Research Strategy, CSL Behring
CIDP
Mel Berger is a Senior Director, Medical Research Strategy at CSL and Adjunct Professor of Pediatrics and Pathology, Case Western Reserve University. He earned his undergraduate, medical and PhD (in Biochemistry) degrees at Case Western Reserve University in Cleveland.
David R. Cornblath, MD
Johns Hopkins University, Baltimore, MD, USA
David R. Cornblath, MD
Johns Hopkins University, Baltimore, MD, USA
GBS
David R. Cornblath received his MD from Case Western Reserve University and completed his residency and fellowship at the Hospital of the University of Pennsylvania under Prof. A.K. Asbury.
Nabil Moumane, MD
Medical Affairs and Pharmacology, CSL Behring
Nabil Moumane, MD
Medical Affairs and Pharmacology, CSL Behring
CIDP
MMN
Nabil Moumane is the Director of Medical Affairs and Pharmacology at CSL Behring.